{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
First approved in 1992
Source:
ANDA078426
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Magnesium Tartrate is magnesium salt of tartaric acid
Status:
Possibly Marketed Outside US
Source:
NCT00483795: Phase 4 Interventional Completed Corneal Staining
Source URL:
First approved in 1992
Source:
21 CFR 358A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Aminomethylpropanol is a synthetic ingredient that functions as a buffer to adjust the pH of cosmetics and personal care products. In cosmetics and personal care products, aminomethylpropanol is used in the formulation of creams and lotions, hair sprays, wave sets, hair dyes and colors, eye and facial products, and other hair and skin care products. The main function of aminomethylpropanol in these products is to establish and hold the pH. The Food and Drug Administration (FDA) includes aminomethylpropanol on its list of indirect food additives as a component of adhesives that are in contact with food. The European Chemicals Agency (ECHA) identifies that “substance causes serious eye irritation, is harmful to aquatic life with long lasting effects and causes skin irritation, causes serious eye damage.” Toxicologically significant concentrations of AMP are unlikely to be achieved in the systemic circulation and/or target tissues in humans as a result of dermal application of products containing aminomethylpropanol. Systemically absorbed dose will be rapidly eliminated from the body with little remaining at the application site.
Status:
Possibly Marketed Outside US
First approved in 1992
Source:
21 CFR 331
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Adipic acid has been incorporated into controlled-release formulation matrix tablets to obtain a pH-independent release for both weakly basic and weakly acidic drugs. It has also been incorporated into the polymeric coating of hydrophilic monolithic systems to modulate the intragel pH, resulting in zero-order release of hydrophilic drugs. The disintegration at intestinal pH of the enteric polymer shellac has been reported to improve when adipic acid was used as a pore-forming agent without affecting release in the acidic media. Adipic acid is used to make bisobrin an antifibrinolytic.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 1992
Source:
ANDA211143
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
HERBALIFE SKIN 7 DAY RESULTS KIT
Source URL:
First approved in 1992
Source:
21 CFR 358H
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Glycol distereate is the diester of stearic acid and ethylene glycol. It is used in cosmetic products (creams, shampoos, moisturizers, soaps) because of its pearlescent, opacity and moisturizing effects as well as its high foaming capacity. It is also used as a food additive. There are no known safety concerns.
Status:
US Approved Rx
(2006)
Source:
NDA021902
(2006)
Source URL:
First approved in 1992
Source:
21 CFR 358A
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
Source:
MIVACRON by ABBVIE
(1992)
Source URL:
First approved in 1992
Source:
MIVACRON by ABBVIE
Source URL:
Class:
MIXTURE
Conditions:
Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine. MIVACRON (a mixture of three stereoisomers) binds competitively to cholinergic receptors on the
motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular
transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. MIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients,
as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle
relaxation during surgery or mechanical ventilation.
Status:
Possibly Marketed Outside US
Source:
ANDA091643
(1992)
Source URL:
First approved in 1992
Source:
ANDA091643
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
A-TEAM by mybody
(2014)
Source URL:
First approved in 1992
Source:
21 CFR 333D
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA204161
(1992)
Source URL:
First approved in 1992
Source:
ANDA204161
Source URL:
Class:
MIXTURE